Reproducibility and rigor in rheumatology research

Frontiers in Medicine

Medicine

Nadia J. Sweis¹  Peter Korsten²  Israel Rubinstein³  Christian Ascoli³  Fatima Alnaimat⁴  Nadera J. Sweiss⁵  Jaleel Jerry G. Sweis⁶ 

[1] Department of Business Administration, King Talal School of Business Technology, Princess Sumaya University for Technology, Amman, Jordan;Department of Nephrology and Rheumatology, University Medical Center Göttingen, Göttingen, Germany;Division of Pulmonary, Critical Care, Sleep, and Allergy, Department of Medicine, University of Illinois Chicago, Chicago, IL, United States;Division of Rheumatology, Department of Medicine, The University of Jordan, Amman, Jordan;Division of Rheumatology, Department of Medicine, University of Illinois Chicago, Chicago, IL, United States;School of Medicine, The University of Jordan, Amman, Jordan;

关键词: clinical trials;    real-world data;    registry;    ethics;    responsible conduct;    research integrity;   

DOI  :  10.3389/fmed.2022.1073551

 received in 2022-10-18, accepted in 2022-12-15,  发布年份 2023

来源: Frontiers

【 摘 要 】

The pillars of scientific progress in rheumatology are experimentation and observation, followed by the publication of reliable and credible results. These data must then be independently verified, validated, and replicated. Peer and journal-specific technical and statistical reviews are paramount to improving rigor and reproducibility. In addition, research integrity, ethics, and responsible conduct training can help to reduce research misconduct and improve scientific evidence. As the number of published articles in rheumatology grows, the field has become critical for determining reproducibility. Prospective, longitudinal, randomized controlled clinical trials are the gold standard for evaluating clinical intervention efficacy and safety in this space. However, their applicability to larger, more representative patient populations with rheumatological disorders worldwide could be limited due to time, technical, and cost constraints involved with large-scale clinical trials. Accordingly, analysis of real-world, patient-centered clinical data retrieved from established healthcare inventories, such as electronic health records, medical billing reports, and disease registries, are increasingly used to report patient outcomes. Unfortunately, it is unknown whether this clinical research paradigm in rheumatology could be deployed in medically underserved regions.

【 授权许可】

Unknown   
Copyright © 2023 Alnaimat, Sweis, Sweis, Ascoli, Korsten, Rubinstein and Sweiss.